Press Releases

Latest

AstraZeneca listed as one of the world’s top-100 most sustainable companies and recognised for its three-fold increase in renewable energy usage
23 January 2018
Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
19 January 2018
Fasenra receives approval in Japan
19 January 2018
Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer
12 January 2018
AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma
10 January 2018
US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
18 December 2017
AstraZeneca to highlight its commitment to blood cancers at the 2017 American Society of Hematology Annual Meeting
6 December 2017
Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients
4 December 2017
The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer
28 November 2017
AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan
27 November 2017

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2011 so you should be able to find just what you are looking for.

Explore archive

Contact us

Karen Birmingham

Director Global Science Media

+44 203 749 5634

Rob Skelding

Director Global Media Relations

+44 203 749 5821

Matthew Kent

Director Global Media Relations

+44 203 749 5906

Gonzalo Viña

Director Global Media Relations

+44 203 749 5916

Jacob Lund

Director External Communications, Sweden

+46 8 553 260 20

Lotta Sjösten

Manager Media Relations, Sweden

+46 8 553 271 10

US Media Team

+1 302 885 2677

Press Releases

Contact us

Subscribe

Follow us

LinkedIn